{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:45:47Z","timestamp":1784666747804,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ijantimicag.2014.12.027","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T12:03:23Z","timestamp":1423310603000},"page":"496-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Pharmacokinetic\/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis"],"prefix":"10.1016","volume":"45","author":[{"given":"Lindsey","family":"te Brake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiati","family":"Dian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Rizal","family":"Ganiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien","family":"Ruesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier","family":"Donders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rovina","family":"Ruslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinout","family":"van Crevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0155","series-title":"Global tuberculosis report 2013","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0160","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1474-4422(13)70168-6","article-title":"Tuberculous meningitis: more questions, still too few answers","volume":"12","author":"Thwaites","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0165","series-title":"Treatment of tuberculosis: guidelines for national programmes","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jinf.2009.06.011","article-title":"British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children","volume":"59","author":"Thwaites","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0175","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","article-title":"Cerebrospinal fluid concentrations of antituberculosis agents in adults and children","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0185","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1378\/chest.120.5.1520","article-title":"Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy","volume":"120","author":"Mehta","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0190","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0195","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0200","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/infdis\/jir658","article-title":"Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability","volume":"204","author":"Srivastava","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/cis353","article-title":"Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy","volume":"55","author":"Pasipanodya","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0210","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0215","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0220","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/AAC.00064-11","article-title":"Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis","volume":"55","author":"Thwaites","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0225","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1128\/AAC.02468-12","article-title":"Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients","volume":"57","author":"Burhan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0230","series-title":"Rapid advice\u2014treatment of tuberculosis in children","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0235","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.01550-06","article-title":"Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients","volume":"51","author":"Ruslami","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0240","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics\u2013pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0245","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1128\/AAC.00912-12","article-title":"Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis","volume":"56","author":"Rosenthal","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0250","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1164\/rccm.201207-1210OC","article-title":"Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model","volume":"187","author":"de Steenwinkel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0255","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/AAC.01474-06","article-title":"Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears","volume":"51","author":"Diacon","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0260","first-page":"305","article-title":"Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review","volume":"15","author":"Steingart","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0265","first-page":"242604","article-title":"Initial antituberculous regimen with better drug penetration into cerebrospinal fluid reduces mortality in HIV infected patients with tuberculous meningitis: data from an HIV observational cohort study","volume":"2013","author":"Alvarez-Uria","year":"2013","journal-title":"Tuberc Res Treat"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1745-6215-12-25","article-title":"Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial","volume":"12","author":"Heemskerk","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0275","series-title":"Fifth international workshop on clinical pharmacology of TB drugs","article-title":"What is the \u2018right\u2019 dose of rifampin? An interim report","author":"Boeree","year":"2012"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0280","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1128\/AAC.00414-06","article-title":"Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy","volume":"51","author":"Shandil","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0285","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood\u2013cerebrospinal fluid\/blood\u2013brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0290","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jac\/46.4.571","article-title":"Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex","volume":"46","author":"Bemer-Melchior","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0295","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s002849900095","article-title":"In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages","volume":"33","author":"Rastogi","year":"1996","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.ijantimicag.2014.12.027_bib0300","series-title":"45th Union world conference on lung health","article-title":"Pharmacokinetic and safety\/tolerability study of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients","author":"Yunivita","year":"2014"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915000503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915000503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T07:50:18Z","timestamp":1537861818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857915000503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0924857915000503"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.12.027","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic\/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}